Form 4: Halozyme Therapeutics Director Matthew L. Posard Sells 20,000 Shares
SEC Form 4 Filing
Director Matthew L. Posard sold 20,000 shares of Halozyme Therapeutics, Inc. (HALO) in two transactions on June 11 and June 12, 2024.
Summary
- Matthew L. Posard, a director of Halozyme Therapeutics, Inc., sold 10,000 shares of common stock on June 11, 2024, at a weighted average price of $50.011 per share.
- The prices ranged from $50.00 to $50.21.
- Following this transaction, Posard directly owned 109,755 shares, including 20,722 stock units subject to a deferral election.
- On June 12, 2024, Posard sold another 10,000 shares at a weighted average price of $50.619 per share, with prices ranging from $50.50 to $50.935.
- After the second transaction, Posard directly owned 99,755 shares, including the deferred stock units.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock sales by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company directors.
Stakeholder Impact
- Shareholders may interpret the stock sale as a lack of confidence by the director, although it could be for personal financial reasons.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics at a weighted average price of $50.011. |
| 06/12/2024 | Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics at a weighted average price of $50.619. |
| 06/13/2024 | Date of signature by James Oehler, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.